Jones Criteria for Diagnosing Acute Rheumatic Fever

The Jones criteria are a set of clinical guidelines used to diagnose acute rheumatic fever, a potentially serious inflammatory condition triggered by untreated streptococcal throat infection. First published in 1944 by T. Duckett Jones in the Journal of the American Medical Association, the criteria divide the signs and symptoms of the disease into “major” and “minor” categories and require a specific combination of them, along with evidence of a recent strep infection, before a diagnosis can be made.¹ The criteria have been revised multiple times since then, most recently in 2015, and they remain the standard diagnostic framework used worldwide.

Why a Checklist Exists for This Disease

Acute rheumatic fever is notoriously difficult to diagnose because there is no single laboratory test or imaging finding that confirms it. The disease can affect the heart, joints, brain, and skin in various combinations, and many of its symptoms overlap with other conditions. Without a structured framework, doctors risk both overdiagnosis (treating someone for a disease they do not have) and underdiagnosis (missing a case that could progress to permanent heart damage). The Jones criteria solve this by requiring that enough of the disease’s characteristic features be present simultaneously, reducing the chance of a false diagnosis in either direction.

The underlying cause of rheumatic fever is an immune response gone wrong. After a throat infection with group A streptococcus, the immune system produces antibodies to fight the bacteria. In some people, those antibodies also attack the body’s own tissues because certain streptococcal proteins structurally resemble proteins found in the heart, joints, and brain. This phenomenon, called molecular mimicry, drives the inflammation seen in rheumatic fever.² Because this autoimmune process can smolder quietly or flare dramatically, the criteria need to capture a range of presentations.

The Major Criteria

The Jones criteria recognize five major manifestations of acute rheumatic fever. These are the hallmarks of the disease, each reflecting the immune system’s attack on a different organ system. A patient needs either two major manifestations or one major manifestation plus two minor ones (along with evidence of strep infection) for a definitive diagnosis.

Carditis

Inflammation of the heart is the most dangerous feature of rheumatic fever because it can cause lasting valve damage and lead to rheumatic heart disease. Carditis can involve any layer of the heart but most commonly targets the mitral and aortic valves, causing them to leak. In mild cases, the patient may have no symptoms at all, and the valve damage is detectable only through echocardiography. This “subclinical carditis” was not always recognized as a major criterion, but accumulating evidence that Doppler echocardiography can detect significant valve regurgitation before a doctor hears anything with a stethoscope changed that.³ In one study, Doppler detected valve damage in all 19 patients who ultimately had confirmed carditis, while clinical examination caught only 15 of them at baseline.⁴ Recognizing subclinical carditis matters enormously because these patients still need long-term prophylaxis to prevent recurrences that could worsen the damage.

Arthritis

Joint inflammation is the most common feature of acute rheumatic fever and often the symptom that first brings patients to medical attention. The classic pattern is migratory polyarthritis: pain and swelling that move from one large joint to another over the course of days. The knees, ankles, wrists, and elbows are most often affected. One tricky aspect is that the arthritis sometimes does not follow this classic migratory pattern. In populations where rheumatic fever is common, the joint involvement can be monoarticular (affecting a single joint) or can persist in one joint rather than migrating, which can make it look like other forms of arthritis.⁵ The 2015 revision of the criteria addressed this by accepting monoarthritis as a major criterion in populations at moderate or high risk for rheumatic fever.

Sydenham Chorea

This neurological manifestation involves involuntary, purposeless movements of the face, hands, and limbs, along with muscle weakness and emotional instability. It results from antibodies crossing into the brain and attacking structures in the basal ganglia.⁶ Sydenham chorea has a unique place among the major criteria because it can appear weeks or even months after the original strep infection, long after other signs of rheumatic fever have faded. Because of this delay, it can stand alone as sufficient evidence of rheumatic fever even without meeting the full two-major-or-one-major-plus-two-minor rule, as long as other causes of chorea have been ruled out.

Erythema Marginatum and Subcutaneous Nodules

The two skin manifestations of rheumatic fever are both major criteria, though they are rarely seen in clinical practice in countries where the disease has become uncommon. Erythema marginatum is a distinctive rash with pink or red rings that spread outward while clearing in the center, typically appearing on the trunk and proximal limbs. Subcutaneous nodules are small, painless, firm lumps found over bony prominences like the elbows, knees, and spine. Both are strongly associated with carditis and tend to appear in patients with more severe disease.⁷ Their rarity in low-incidence settings means that many clinicians in wealthier countries have never actually seen either one, which is part of why the Jones criteria exist as a structured aid rather than relying on pattern recognition alone.

The Minor Criteria and the Strep Requirement

The minor criteria capture features that are suggestive of rheumatic fever but not specific to it. They include fever, elevated inflammatory markers (such as erythrocyte sedimentation rate or C-reactive protein), a prolonged PR interval on an electrocardiogram, and, in high-risk populations, joint pain without frank arthritis. On their own, these findings could point to dozens of conditions. Their value is in tipping the diagnostic scale when combined with a major criterion.

Crucially, no combination of major or minor manifestations is sufficient without evidence that the patient recently had a group A streptococcal infection. This evidence usually comes from a positive throat culture, a positive rapid antigen test, or elevated streptococcal antibody titers in the blood, most commonly anti-streptolysin O (ASO) and anti-DNase B (ADB). Measuring these antibodies has its own challenges: both can remain elevated for weeks to months after an infection, and the two tests need to be run in parallel, which complicates interpretation.⁸ This slow antibody decay means a positive result does not necessarily mean the infection was recent enough to be causing the current symptoms. Clinicians must weigh the entire picture.

The 2015 Revision and Risk Stratification

For decades, the Jones criteria applied the same rules everywhere in the world. The 2015 revision by the American Heart Association changed that by introducing two separate diagnostic pathways based on whether a patient lives in a low-risk or moderate-to-high-risk population.⁹ In low-risk populations (where rheumatic fever incidence is below about 2 per 100,000 school-age children per year), the criteria remain strict, prioritizing specificity so that the rare case is not overdiagnosed. In moderate-to-high-risk populations, the criteria are loosened to improve sensitivity: monoarthritis and polyarthralgia (joint pain without swelling) can count as major criteria, and subclinical carditis detected by echocardiography is formally recognized as equivalent to clinical carditis.

This split was a direct response to accumulating evidence that in places like sub-Saharan Africa, South Asia, and Indigenous Australian communities, the old criteria were missing real cases. Joint involvement in these populations often did not follow the textbook migratory pattern, and echocardiography was revealing heart valve damage in patients whose doctors heard no murmur. By setting a lower bar for diagnosis in populations where rheumatic fever is common, the revised criteria aim to catch more true cases early enough to prevent permanent heart damage.

The revision also formalized the role of echocardiography in diagnosing carditis. Earlier versions of the criteria relied on clinical examination: a doctor needed to hear a new murmur. The 2015 update acknowledged that Doppler echocardiography is more sensitive and that subclinical carditis identified by ultrasound should be treated just as seriously as clinically apparent disease.¹⁰

Telling Pathologic Regurgitation From Normal Leakage

One of the trickier aspects of using echocardiography in the Jones criteria is that many healthy people have trivial amounts of valve leakage. A study of healthy students found physiologic mitral regurgitation in about 15% of subjects.¹¹ If every trace of leakage were treated as evidence of carditis, the criteria would generate enormous numbers of false positives. To prevent this, strict Doppler criteria have been developed to separate harmless leakage from disease. Pathologic mitral regurgitation in rheumatic fever tends to produce a jet directed posteriorly, with a longer duration and higher velocity than physiologic leakage.¹² Applying these technical thresholds carefully is essential, especially in screening programs that examine large numbers of children.

When the Diagnosis Is Not Clear-Cut

Even with structured criteria, rheumatic fever can be hard to distinguish from other post-streptococcal conditions. Post-streptococcal reactive arthritis is a close mimic: it follows a strep infection, it causes joint inflammation, and it can even be accompanied by mild cardiac involvement. The two conditions sometimes look so similar that researchers have questioned whether they are truly separate diseases or points on a spectrum.¹³ The practical stakes are high: a patient diagnosed with rheumatic fever is placed on long-term antibiotic prophylaxis, while a patient labeled with reactive arthritis generally is not. Getting the distinction wrong in either direction carries real consequences.

Recurrent episodes add another layer of complexity. Someone who has already had rheumatic fever and develops new symptoms after another strep infection may not fit neatly into the standard framework. The 2015 criteria allow for a presumptive diagnosis of recurrence with fewer findings than a first episode requires, because the risk of progressive heart damage with each subsequent attack is so high that erring on the side of caution is justified.¹⁴

Who Gets Rheumatic Fever and Where

Rheumatic fever has virtually disappeared from wealthy countries with good access to healthcare, where strep throat is routinely treated with antibiotics. It remains a major public health problem in low- and middle-income countries and among disadvantaged communities in wealthier nations. The disparities can be staggering. In Australia, Indigenous populations have age-standardized rates of first-ever acute rheumatic fever more than 120 times higher than non-Indigenous Australians.¹⁵ The prevalence of established rheumatic heart disease among Indigenous Australians is more than 60 times the rate in the non-Indigenous population. Mortality data tells a similar story: Indigenous Australians die from rheumatic heart disease at rates that exceed those seen in many industrialized countries a century ago.¹⁶

These numbers reflect overcrowded living conditions that favor strep transmission, limited access to primary care for early antibiotic treatment, and barriers to long-term prophylaxis once rheumatic fever has been diagnosed. The 2015 risk stratification in the Jones criteria was partly designed to address this reality: applying stricter diagnostic thresholds in communities where the disease runs rampant means missing the cases that matter most.

Genetics and Individual Susceptibility

Not everyone who has untreated strep throat develops rheumatic fever. Only a small fraction do, which has long suggested a genetic component to susceptibility. Research has identified signals in the human leukocyte antigen (HLA) region, the part of the genome that governs how the immune system recognizes foreign proteins. In a study of South Asian and European populations, certain variants in HLA-DQB1 were associated with roughly 1.5 to 1.9 times the risk of developing rheumatic heart disease.¹⁷ These are modest effect sizes individually, but they help explain why some families are hit repeatedly while others living in the same conditions are spared. The genetic findings also point back to molecular mimicry: HLA molecules determine which protein fragments the immune system “sees,” and certain HLA types may present streptococcal fragments that happen to look more like the body’s own tissue.

Prevention at Two Levels

Preventing rheumatic fever works on two fronts. Primary prevention means treating strep throat with antibiotics before the immune system has time to mount the damaging autoimmune response. Penicillin remains the first-line treatment, and a single dose of intramuscular penicillin or a 10-day oral course is sufficient to prevent most cases of rheumatic fever following strep pharyngitis.¹⁸ For patients with penicillin allergy, alternatives include sulfadiazine or macrolide antibiotics.

Secondary prevention is for people who have already had rheumatic fever and need to avoid recurrences. This involves regular injections of benzathine penicillin G, typically every three to four weeks, continued for years. The duration depends on whether the patient had carditis: someone who had heart involvement may need prophylaxis for a decade or even into adulthood, while someone whose rheumatic fever involved only arthritis may have a shorter course.¹⁹ Adherence is a persistent problem worldwide. The injections are painful, they must be repeated for years, and many patients live far from clinics. Studies consistently show that missed doses are common, especially in the very populations where rheumatic fever is most prevalent.

Screening With Portable Echocardiography

Because the Jones criteria can only diagnose acute episodes, they do not capture children who had a mild or unrecognized attack and are now silently developing rheumatic heart disease. This gap has driven interest in echocardiographic screening programs. The idea is to bring portable ultrasound machines into schools or community settings in high-risk areas, scan large numbers of children, and identify subclinical valve disease before it progresses to heart failure.

Cost-effectiveness analyses have generally been favorable. A study modeling screening in Brazil using handheld devices operated by non-physicians, with remote interpretation via telemedicine, found that the program was cost-effective over a 30-year time horizon and well below Brazil’s accepted cost-effectiveness threshold.²⁰ A separate modeling study found that screening was likely to save money compared with no screening, with over an 80% probability of being both less costly and more effective.²¹ The economics hinge on what happens to children identified with subclinical disease: if they can be placed on secondary prophylaxis early and avoid progression to severe valve damage requiring surgery, the savings are substantial. If adherence to prophylaxis remains poor, the benefits shrink.

The Vaccine Problem

The ultimate solution to rheumatic fever would be a vaccine against group A streptococcus. Despite decades of effort, no licensed vaccine exists. The core difficulty is the same molecular mimicry that causes rheumatic fever in the first place: streptococcal surface proteins resemble human proteins closely enough that a vaccine designed to generate antibodies against the bacterium could theoretically trigger the very autoimmune response it is meant to prevent. Any candidate vaccine must demonstrate that it does not elicit antibodies that cross-react with human heart or brain tissue.²² Several approaches are in early-stage testing, including vaccines that target toxins produced by the bacterium rather than its surface proteins, sidestepping the mimicry issue. But progress has been slow, and a licensed product is likely still years away. In the meantime, the Jones criteria remain the front line for identifying and managing a disease that, for much of the world, never went away.